Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
DJS Law Group issued a shareholder-solicitation notice announcing a securities class action against Capricor Therapeutics alleging violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5. The complaint alleges Capricor made false and misleading statements about deramiocel's progress toward FDA approval while aware of adverse data from its Phase 2 HOPE-2 trial, with a stated class period of October 9, 2024 through July 10, 2025.
Key figures
- Statutes cited
- Sections 10(b) and 20(a) of the Securities Exchange Act of 1934; Rule 10b-5
- Class period end
- July 10, 2025
- Class period start
- October 9, 2024
- Lead plaintiff deadline
- September 15, 2025
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.